Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) saw a large increase in short interest in the month of July. As of July 31st, there was short interest totaling 474 shares, an increase of 169.3% from the July 15th total of 176 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days. Currently, 0.0% of the company’s stock are short sold.
Basilea Pharmaceutica Stock Performance
BPMUF opened at $65.50 on Friday. The stock has a fifty day moving average of $61.47 and a 200-day moving average of $66.83. Basilea Pharmaceutica has a 12-month low of $59.29 and a 12-month high of $74.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.68 and a current ratio of 5.11.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.
See Also
- Five stocks we like better than Basilea Pharmaceutica
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
